查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1494859

到 2030 年更年期热潮红市场预测：按产品类型、治疗类型、严重程度、应用、最终用户和地区进行的全球分析

Menopausal Hot Flashes Market Forecasts to 2030 - Global Analysis By Product (Tablets, Patches, Creams & Gels, Injections and Other Products), Treatment Type, Severity, Application, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3个工作天内

价格

根据 Stratistics MRC 的数据，2024 年全球更年期热潮红市场规模为 172.7 亿美元，预计 2030 年将达到 244.5 亿美元，复合年增长率为 7.2%。

更年期热潮红是一种突然的、强烈的热感，通常发生在 40 岁末至 50 岁出头的女性身上，预示着向闭经的过渡。这些热潮红可持续几秒钟到几分钟，并伴随出汗、脸红和心率加快。发生这种情况是因为荷尔蒙波动，尤其是雌激素水平低，会扰乱体温调节。

根据2021年8月发表在《北美更年期协会杂誌》上的一篇论文，据观察，美国更年期血管舒缩症状的盛行率高达77%。

世界老化

随着女性老龄化，她们更有可能出现热潮红（这是更年期的常见症状），从而增加了对缓解这些症状的治疗和疗法的需求。随着越来越多的人进入更年期，旨在缓解热潮红和相关不适的药物、荷尔蒙疗法和替代疗法的市场不断增长。这些人口变化增强了人们对更年期健康的兴趣，并加速了更年期热潮红市场的创新和研发投资。

安全问题

由于乳癌、血栓和中风等潜在风险，更年期热潮红市场的安全问题围绕着荷尔蒙补充疗法的使用。此外，人们也担心草药补充品等替代疗法的有效性和安全性。这些安全问题影响了患者的信心，导致采用率降低，医疗保健提供者不愿开出某些治疗方法，阻碍了市场的成长。

现代生活方式

现代生活方式的特征是压力、不规律的睡眠模式和不健康的饮食习惯，导致女性荷尔蒙失衡，并加剧热潮红等更年期症状。久坐的生活方式和环境因素的增加也起了一定的作用。製药公司正在透过创新疗法来满足这些不断增长的消费者需求。随着女性寻求有效的解决方案来控制症状和维持生活质量，针对更年期热潮红的产品市场正在迅速扩大。

增加替代疗法的可用性

更年期热潮红的替代疗法，如草药补充品、针灸和生活方式改变，正变得越来越可用，这对传统药物治疗的发展提出了挑战。此外，一些替代疗法的功效和安全性尚未得到充分研究或监管，这给患者和医疗保健提供者带来了不确定性。这种转变减少了对传统药物的需求并影响市场成长。

COVID-19 的影响

COVID-19 大流行透过扰乱医疗服务、延迟诊断和减少患者就诊来影响更年期热潮红市场。供应链中断正在影响药物和治疗的取得。经济不确定性导致患者面临经济困难，影响他们接受治疗的能力。然而，远端医疗和虚拟咨询的普及透过提供替代的医疗保健访问选项部分缓解了这些挑战。

荷尔蒙治疗领域预计在预测期内将是最大的

荷尔蒙治疗领域预计将出现良好的成长。更年期热潮红的荷尔蒙治疗通常涉及荷尔蒙补充疗法（HRT），即单独使用雌激素或与黄体酮联合使用。这些治疗可以帮助调节荷尔蒙水平并缓解热潮红等症状。 HRT 以锭剂、贴片、凝胶、乳霜等形式施用。儘管有效，但它可能带来血栓、中风和乳癌等风险，因此通常建议在医疗监督下使用最短的必要时间。

预测期内荷尔蒙疗法的女性族群预计复合年增长率最高

预计接受荷尔蒙疗法的女性在预测期内的复合年增长率最高。接受荷尔蒙疗法（HT）的女性更年期热潮红可以透过雌激素或雌激素和黄体激素的组合来有效控制。透过稳定荷尔蒙水平，HT 可以帮助减少热潮红的频率和严重程度。然而，荷尔蒙疗法有副作用，并不适合所有人。考虑进行 HT 的女性应与医疗保健提供者讨论风险和益处，以确定针对其症状的最佳选择。

比最大的地区

预计亚太地区在预测期内将占据最大的市场占有率。人们对更年期健康意识的提高和人口老化的加剧，尤其是在日本和韩国等国家，正在推动市场扩张。采用西方生活方式，包括饮食改变和久坐习惯，导致更年期症状的盛行率增加。然而，远距远端医疗的进步和医疗基础设施的改善正在逐渐解决这些障碍并支持市场开拓。

复合年增长率最高的地区：

预计北美在预测期内的复合年增长率最高。该地区人口老化以及对更年期症状和管理的认识不断提高，对有效治疗的需求不断增加。儘管医学技术进步提供了创新的解决方案，但荷尔蒙疗法的安全问题仍然存在。北美市场仍然是一个重要的市场，有许多治疗方案可以满足更年期热潮红女性的需求。

免费客製化服务：

订阅此报告的客户可以利用以下免费自订选项之一：

  • 公司简介
    • 其他市场参与企业的综合分析（最多 3 家公司）
    • 主要企业SWOT分析（最多3家企业）
  • 区域分割
    • 根据客户兴趣对主要国家的市场估计/预测/复合年增长率（註：基于可行性检查）
  • 竞争基准化分析
    • 按产品系列、地理分布和策略联盟对主要企业基准化分析

目录

第一章执行概述

第二章 前言

  • 概述
  • 相关利益者
  • 调查范围
  • 调查方法
    • 资料探勘
    • 资料分析
    • 资料检验
    • 研究途径
  • 研究资讯来源
    • 主要研究资讯来源
    • 二次研究资讯来源
    • 先决条件

第三章市场趋势分析

  • 介绍
  • 促进因素
  • 抑制因素
  • 机会
  • 威胁
  • 产品分析
  • 应用分析
  • 最终用户分析
  • 新兴市场
  • COVID-19 的影响

第4章波特五力分析

  • 供应商的议价能力
  • 买方议价能力
  • 替代品的威胁
  • 新进入者的威胁
  • 竞争公司之间的敌对关係

第五章全球更年期热潮红市场：依产品

  • 介绍
  • 锭剂
  • 修补
  • 霜和凝胶
  • 注射
  • 其他的

第六章全球更年期热潮红市场：依治疗类型

  • 介绍
  • 荷尔蒙治疗
    • 雌激素替代疗法
    • 黄体酮替代疗法
    • 联合治疗
  • 非荷尔蒙治疗
    • 抗忧郁症
    • 抗惊厥药
    • 降血压
  • 非处方药 (OTC)
    • 草药补充品
    • 维生素和矿物质
    • 植物雌激素
  • 替代疗法
    • 针刺
    • 瑜伽和锻炼计划
    • 行为疗法

第七章全球更年期热潮红市场：依严重程度分类

  • 介绍
  • 温和的
  • 缓和
  • 严重

第八章全球更年期热潮红市场：依应用分类

  • 介绍
  • 闭经妇女
  • 乳癌患者
  • 接受荷尔蒙疗法的女性
  • 其他的

第九章全球更年期热潮红市场：依最终用户分类

  • 介绍
  • 医院
  • 居家医疗
  • 专科诊所
  • 其他的

第十章全球更年期热潮红市场：按地区

  • 介绍
  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 义大利
    • 法国
    • 西班牙
    • 欧洲其他地区
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 纽西兰
    • 韩国
    • 其他亚太地区
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地区
  • 中东/非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 卡达
    • 南非
    • 其他中东/非洲

第十一章 主要进展

  • 合约、伙伴关係、协作和合资企业
  • 收购和合併
  • 新产品发布
  • 业务扩展
  • 其他关键策略

第十二章 公司概况

  • Pfizer Inc.
  • Allergan PLC
  • Bayer AG
  • Novartis AG
  • GlaxoSmithKline PLC
  • Johnson & Johnson
  • Novo Nordisk A/S
  • Teva Pharmaceutical Industries Limited
  • Mylan NV
  • Amgen Inc.
  • Merck & Co Inc.
  • Perrigo Company
  • Astellas Pharma Inc.
  • TherapeuticsMD Inc.
  • Hisamitsu Pharmaceutical Corporation
  • Endo International PLC
Product Code: SMRC26379

According to Stratistics MRC, the Global Menopausal Hot Flashes Market is accounted for $17.27 billion in 2024 and is expected to reach $24.45 billion by 2030 growing at a CAGR of 7.2% during the forecast period. Menopausal hot flashes are sudden, intense feelings of heat that typically affect women in their late 40s to early 50s, marking the transition into menopause. These flashes can last from a few seconds to several minutes, accompanied by sweating, flushing of the face, and a rapid heartbeat. They are caused by hormonal fluctuations, particularly a decline in estrogen levels, which disrupt the body's temperature regulation.

According to an article published in the Journal of the North American Menopause Society in August 2021, it has been observed that the prevalence of vasomotor menopausal symptoms was high in the United States with 77%.

Market Dynamics:

Driver:

Global aging population

As women age, they are more likely to experience hot flashes, a common symptom of menopause, driving the demand for treatments and therapies to alleviate these symptoms. With a larger demographic entering menopausal age brackets, there's an increased market for pharmaceuticals, hormone therapies, and alternative remedies aimed at alleviating hot flashes and related discomfort. This demographic shift amplifies the focus on menopausal health, spurring innovation and investment in research and development within the menopausal hot flashes market.

Restraint:

Safety concerns

Safety concerns in the menopausal hot flashes market primarily revolve around the use of hormone replacement therapies due to potential risks such as increased likelihood of breast cancer, blood clots, and stroke. Additionally, there are concerns regarding the efficacy and safety of alternative treatments such as herbal supplements. These safety concerns hinder market growth by impacting patient confidence, leading to decreased adoption rates and reluctance among healthcare providers to prescribe certain treatments.

Opportunity:

Mounting modern lifestyles

Mounting modern lifestyles, characterized by stress, erratic sleep patterns, and unhealthy dietary habits, contribute to hormonal imbalances in women, exacerbating menopausal symptoms like hot flashes. Increased prevalence of sedentary lifestyles and environmental factors also play a role. Pharmaceutical companies respond with innovative treatments and therapies to address this growing consumer need. As women seek effective solutions to manage their symptoms and maintain their quality of life, the market for products targeting menopausal hot flashes expands rapidly.

Threat:

Rising availability of alternative therapies

The increasing availability of alternative therapies for menopausal hot flashes, such as herbal supplements, acupuncture, and lifestyle changes, poses a challenge to the growth of traditional pharmaceutical treatments. Additionally, the efficacy and safety of some alternative therapies may not be thoroughly researched or regulated, leading to uncertainties among patients and healthcare providers. This shift reduces demand for conventional medications, impacting market growth.

Covid-19 Impact

The covid-19 pandemic has impacted the menopausal hot flashes market by disrupting healthcare services, delaying diagnosis, and reducing patient visits. Supply chain disruptions have affected the availability of medications and treatments. Economic uncertainties have led to financial constraints among patients, affecting their ability to afford treatments. However, increased telemedicine adoption and virtual consultations have partially mitigated these challenges by providing alternative healthcare access options.

The hormonal treatment segment is expected to be the largest during the forecast period

The hormonal treatment segment is estimated to have a lucrative growth. Hormonal treatments for menopausal hot flashes often involve hormone replacement therapy (HRT), which includes estrogen alone or combined with progesterone. These treatments help regulate hormone levels, alleviating symptoms like hot flashes. HRT can be administered through pills, patches, gels, or creams. It's effective but may carry risks such as blood clots, stroke, or breast cancer, so it's usually recommended for the shortest duration necessary and under medical supervision.

The women on hormone therapy segment is expected to have the highest CAGR during the forecast period

The women on hormone therapy segment is anticipated to witness the highest CAGR growth during the forecast period. Menopausal hot flashes in women on hormone therapy (HT) can be effectively managed with estrogen or a combination of estrogen and progestin. HT helps reduce the frequency and severity of hot flashes by stabilizing hormone levels. However, it may have side effects and is not suitable for everyone. Women considering HT should discuss risks and benefits with their healthcare provider to determine the best course of action for their symptoms.

Region with largest share:

Asia Pacific is projected to hold the largest market share during the forecast period. Increasing awareness about menopausal health, coupled with a rising aging population, particularly in countries like Japan and South Korea, is driving market expansion. The adoption of Western lifestyles, including dietary changes and sedentary habits, is contributing to a higher prevalence of menopausal symptoms. Nevertheless, advancements in telemedicine and increasing healthcare infrastructure are gradually addressing these barriers, fostering market development.

Region with highest CAGR:

North America is projected to have the highest CAGR over the forecast period. The region's aging population, combined with a high level of awareness about menopausal symptoms and their management, drives demand for effective treatments. Technological advancements in pharmaceuticals offer innovative solutions, although safety concerns regarding hormone therapy persist. The market in North America remains significant, with a range of treatment options available to cater to the needs of women experiencing menopausal hot flashes.

Key players in the market

Some of the key players profiled in the Menopausal Hot Flashes Market include Pfizer Inc., Allergan PLC, Bayer AG, Novartis AG, GlaxoSmithKline PLC, Johnson & Johnson, Novo Nordisk A/S, Teva Pharmaceutical Industries Limited, Mylan N.V., Amgen Inc., Merck & Co Inc., Perrigo Company, Astellas Pharma Inc., TherapeuticsMD Inc., Hisamitsu Pharmaceutical Corporation and Endo International PLC.

Key Developments:

In May 2023, Astellas Pharma Inc. announced that the U.S. Food and Drug Administration (FDA) has approved VEOZAHTM (fezolinetant) 45 mg once daily for the treatment of moderate to severe vasomotor symptoms (VMS) due to menopause1. VEOZAH is the first nonhormonal neurokinin 3 (NK3) receptor antagonist approved to treat VMS due to menopause.

Products Covered:

  • Tablets
  • Patches
  • Creams & Gels
  • Injections
  • Other Products

Treatment Types Covered:

  • Hormonal Treatment
  • Non-Hormonal Treatment
  • Over-the-Counter (OTC) Products
  • Alternative Therapies

Severities Covered:

  • Mild
  • Moderate
  • Severe

Applications Covered:

  • Perimenopausal & Postmenopausal Women
  • Breast Cancer Patients
  • Women on Hormone Therapy
  • Other Applications

End Users Covered:

  • Hospitals
  • Homecare
  • Specialty Clinics
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2022, 2023, 2024, 2026, and 2030
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Product Analysis
  • 3.7 Application Analysis
  • 3.8 End User Analysis
  • 3.9 Emerging Markets
  • 3.10 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Menopausal Hot Flashes Market, By Product

  • 5.1 Introduction
  • 5.2 Tablets
  • 5.3 Patches
  • 5.4 Creams & Gels
  • 5.5 Injections
  • 5.6 Other Products

6 Global Menopausal Hot Flashes Market, By Treatment Type

  • 6.1 Introduction
  • 6.2 Hormonal Treatment
    • 6.2.1 Estrogen Replacement Therapy
    • 6.2.2 Progesterone Replacement Therapy
    • 6.2.3 Combination Therapy
  • 6.3 Non-Hormonal Treatment
    • 6.3.1 Antidepressants
    • 6.3.2 Anticonvulsants
    • 6.3.3 Antihypertensives
  • 6.4 Over-the-Counter (OTC) Products
    • 6.4.1 Herbal Supplements
    • 6.4.2 Vitamins & Minerals
    • 6.4.3 Phytoestrogens
  • 6.5 Alternative Therapies
    • 6.5.1 Acupuncture
    • 6.5.2 Yoga & Exercise Programs
    • 6.5.3 Behavioral Therapies

7 Global Menopausal Hot Flashes Market, By Severity

  • 7.1 Introduction
  • 7.2 Mild
  • 7.3 Moderate
  • 7.4 Severe

8 Global Menopausal Hot Flashes Market, By Application

  • 8.1 Introduction
  • 8.2 Perimenopausal & Postmenopausal Women
  • 8.3 Breast Cancer Patients
  • 8.4 Women on Hormone Therapy
  • 8.5 Other Applications

9 Global Menopausal Hot Flashes Market, By End User

  • 9.1 Introduction
  • 9.2 Hospitals
  • 9.3 Homecare
  • 9.4 Specialty Clinics
  • 9.5 Other End Users

10 Global Menopausal Hot Flashes Market, By Geography

  • 10.1 Introduction
  • 10.2 North America
    • 10.2.1 US
    • 10.2.2 Canada
    • 10.2.3 Mexico
  • 10.3 Europe
    • 10.3.1 Germany
    • 10.3.2 UK
    • 10.3.3 Italy
    • 10.3.4 France
    • 10.3.5 Spain
    • 10.3.6 Rest of Europe
  • 10.4 Asia Pacific
    • 10.4.1 Japan
    • 10.4.2 China
    • 10.4.3 India
    • 10.4.4 Australia
    • 10.4.5 New Zealand
    • 10.4.6 South Korea
    • 10.4.7 Rest of Asia Pacific
  • 10.5 South America
    • 10.5.1 Argentina
    • 10.5.2 Brazil
    • 10.5.3 Chile
    • 10.5.4 Rest of South America
  • 10.6 Middle East & Africa
    • 10.6.1 Saudi Arabia
    • 10.6.2 UAE
    • 10.6.3 Qatar
    • 10.6.4 South Africa
    • 10.6.5 Rest of Middle East & Africa

11 Key Developments

  • 11.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 11.2 Acquisitions & Mergers
  • 11.3 New Product Launch
  • 11.4 Expansions
  • 11.5 Other Key Strategies

12 Company Profiling

  • 12.1 Pfizer Inc.
  • 12.2 Allergan PLC
  • 12.3 Bayer AG
  • 12.4 Novartis AG
  • 12.5 GlaxoSmithKline PLC
  • 12.6 Johnson & Johnson
  • 12.7 Novo Nordisk A/S
  • 12.8 Teva Pharmaceutical Industries Limited
  • 12.9 Mylan N.V.
  • 12.10 Amgen Inc.
  • 12.11 Merck & Co Inc.
  • 12.12 Perrigo Company
  • 12.13 Astellas Pharma Inc.
  • 12.14 TherapeuticsMD Inc.
  • 12.15 Hisamitsu Pharmaceutical Corporation
  • 12.16 Endo International PLC

List of Tables

  • Table 1 Global Menopausal Hot Flashes Market Outlook, By Region (2022-2030) ($MN)
  • Table 2 Global Menopausal Hot Flashes Market Outlook, By Product (2022-2030) ($MN)
  • Table 3 Global Menopausal Hot Flashes Market Outlook, By Tablets (2022-2030) ($MN)
  • Table 4 Global Menopausal Hot Flashes Market Outlook, By Patches (2022-2030) ($MN)
  • Table 5 Global Menopausal Hot Flashes Market Outlook, By Creams & Gels (2022-2030) ($MN)
  • Table 6 Global Menopausal Hot Flashes Market Outlook, By Injections (2022-2030) ($MN)
  • Table 7 Global Menopausal Hot Flashes Market Outlook, By Other Products (2022-2030) ($MN)
  • Table 8 Global Menopausal Hot Flashes Market Outlook, By Treatment Type (2022-2030) ($MN)
  • Table 9 Global Menopausal Hot Flashes Market Outlook, By Hormonal Treatment (2022-2030) ($MN)
  • Table 10 Global Menopausal Hot Flashes Market Outlook, By Estrogen Replacement Therapy (2022-2030) ($MN)
  • Table 11 Global Menopausal Hot Flashes Market Outlook, By Progesterone Replacement Therapy (2022-2030) ($MN)
  • Table 12 Global Menopausal Hot Flashes Market Outlook, By Combination Therapy (2022-2030) ($MN)
  • Table 13 Global Menopausal Hot Flashes Market Outlook, By Non-Hormonal Treatment (2022-2030) ($MN)
  • Table 14 Global Menopausal Hot Flashes Market Outlook, By Antidepressants (2022-2030) ($MN)
  • Table 15 Global Menopausal Hot Flashes Market Outlook, By Anticonvulsants (2022-2030) ($MN)
  • Table 16 Global Menopausal Hot Flashes Market Outlook, By Antihypertensives (2022-2030) ($MN)
  • Table 17 Global Menopausal Hot Flashes Market Outlook, By Over-the-Counter (OTC) Products (2022-2030) ($MN)
  • Table 18 Global Menopausal Hot Flashes Market Outlook, By Herbal Supplements (2022-2030) ($MN)
  • Table 19 Global Menopausal Hot Flashes Market Outlook, By Vitamins & Minerals (2022-2030) ($MN)
  • Table 20 Global Menopausal Hot Flashes Market Outlook, By Phytoestrogens (2022-2030) ($MN)
  • Table 21 Global Menopausal Hot Flashes Market Outlook, By Alternative Therapies (2022-2030) ($MN)
  • Table 22 Global Menopausal Hot Flashes Market Outlook, By Acupuncture (2022-2030) ($MN)
  • Table 23 Global Menopausal Hot Flashes Market Outlook, By Yoga & Exercise Programs (2022-2030) ($MN)
  • Table 24 Global Menopausal Hot Flashes Market Outlook, By Behavioral Therapies (2022-2030) ($MN)
  • Table 25 Global Menopausal Hot Flashes Market Outlook, By Mild (2022-2030) ($MN)
  • Table 26 Global Menopausal Hot Flashes Market Outlook, By Moderate (2022-2030) ($MN)
  • Table 27 Global Menopausal Hot Flashes Market Outlook, By Severe (2022-2030) ($MN)
  • Table 28 Global Menopausal Hot Flashes Market Outlook, By Application (2022-2030) ($MN)
  • Table 29 Global Menopausal Hot Flashes Market Outlook, By Perimenopausal & Postmenopausal Women (2022-2030) ($MN)
  • Table 30 Global Menopausal Hot Flashes Market Outlook, By Breast Cancer Patients (2022-2030) ($MN)
  • Table 31 Global Menopausal Hot Flashes Market Outlook, By Women on Hormone Therapy (2022-2030) ($MN)
  • Table 32 Global Menopausal Hot Flashes Market Outlook, By Other Applications (2022-2030) ($MN)
  • Table 33 Global Menopausal Hot Flashes Market Outlook, By End User (2022-2030) ($MN)
  • Table 34 Global Menopausal Hot Flashes Market Outlook, By Hospitals (2022-2030) ($MN)
  • Table 35 Global Menopausal Hot Flashes Market Outlook, By Homecare (2022-2030) ($MN)
  • Table 36 Global Menopausal Hot Flashes Market Outlook, By Specialty Clinics (2022-2030) ($MN)
  • Table 37 Global Menopausal Hot Flashes Market Outlook, By Other End Users (2022-2030) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.